These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 10971110)

  • 61. How effective are current therapies for acromegaly?
    Freda PU
    Growth Horm IGF Res; 2003 Aug; 13 Suppl A():S144-51. PubMed ID: 12914744
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly.
    Colao A; Auriemma RS; Pivonello R; Kasuki L; Gadelha MR
    Pituitary; 2016 Jun; 19(3):235-47. PubMed ID: 26519143
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
    Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cabergoline in acromegaly.
    Kuhn E; Chanson P
    Pituitary; 2017 Feb; 20(1):121-128. PubMed ID: 28025719
    [TBL] [Abstract][Full Text] [Related]  

  • 65. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
    Colao A; Pivonello R; Rosato F; Tita P; De Menis E; Barreca A; Ferrara R; Mainini F; Arosio M; Lombardi G
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):342-51. PubMed ID: 16487447
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cabergoline therapy of growth hormone & growth hormone/prolactin secreting pituitary tumors.
    Freda PU; Reyes CM; Nuruzzaman AT; Sundeen RE; Khandji AG; Post KD
    Pituitary; 2004; 7(1):21-30. PubMed ID: 15638294
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl.
    Rix M; Laurberg P; Hoejberg AS; Brock-Jacobsen B
    Eur J Endocrinol; 2005 Aug; 153(2):195-201. PubMed ID: 16061823
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Somatostatin receptors in pituitary function, diagnosis and therapy.
    Hofland LJ; Lamberts SW
    Front Horm Res; 2004; 32():235-52. PubMed ID: 15281350
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
    Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma.
    Cannavò S; Squadrito S; Curtò L; Almoto B; Trimarchi F
    Horm Metab Res; 2001 Oct; 33(10):618-24. PubMed ID: 11607883
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Treatment of pituitary gland hyperfunction: from acromegaly to prolactinoma].
    Schäffler A
    Internist (Berl); 2006 Dec; 47(12):1215-6, 1218-20, 1222. PubMed ID: 17033781
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Management of endocrine disease: GH excess: diagnosis and medical therapy.
    Andersen M
    Eur J Endocrinol; 2014 Jan; 170(1):R31-41. PubMed ID: 24144967
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors.
    Korbonits M; Jacobs RA; Aylwin SJ; Burrin JM; Dahia PL; Monson JP; Honegger J; Fahlbush R; Trainer PJ; Chew SL; Besser GM; Grossman AB
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3624-30. PubMed ID: 9768675
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Hormone secretion by pituitary adenomas is characterized by increased disorderliness and spikiness but more regular pulsing.
    Roelfsema F; Pereira AM; Biermasz NR; Veldhuis JD
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3836-44. PubMed ID: 25014002
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT.
    Pirker W; Riedl M; Luger A; Czech T; Rössler K; Asenbaum S; Angelberger P; Kornhuber J; Deecke L; Podreka I; Brücke T
    J Nucl Med; 1996 Dec; 37(12):1931-7. PubMed ID: 8970508
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Medical therapy of pituitary adenomas: effects on tumor shrinkage.
    Colao A; Pivonello R; Di Somma C; Savastano S; Grasso LF; Lombardi G
    Rev Endocr Metab Disord; 2009 Jun; 10(2):111-23. PubMed ID: 18791829
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly.
    Colao A; Auriemma RS; Pivonello R
    Pituitary; 2016 Apr; 19(2):210-21. PubMed ID: 26290466
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Disappearance of a growth hormone secreting macro adenoma during long-term somatostatin analogue administration and recurrence following somatostatin withdrawal.
    Livadas S; Hadjidakis DJ; Argyropoulou MI; Stamatelatou M; Kelekis D; Raptis SA
    Hormones (Athens); 2006; 5(1):57-63. PubMed ID: 16728386
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Management of pituitary tumors.
    Shimon I; Melmed S
    Ann Intern Med; 1998 Sep; 129(6):472-83. PubMed ID: 9735086
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Characterization of the ability of a, second-generation SST-DA chimeric molecule, TBR-065, to suppress GH secretion from human GH-secreting adenoma cells.
    Cuny T; Graillon T; Defilles C; Datta R; Zhang S; Figarella-Branger D; Dufour H; Mougel G; Brue T; Landsman T; Halem HA; Culler MD; Barlier A; Saveanu A
    Pituitary; 2021 Jun; 24(3):351-358. PubMed ID: 33433890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.